Arturo Rafael Castro, MD

61% fewer Medicare Part D claims than the average endocrinology, diabetes & metabolism physician in 2024

1,033 Medicare Part D claims for 167 beneficiaries, against an average of 2,630 among the 8,223 providers of this specialty who prescribed in Part D. Brand-name drugs were 69% of claims.

Most prescribed

1. Trulicity127 claims
2. Ozempic112 claims
3. Levothyroxine Sodium96 claims
4. Tresiba Flextouch U-20050 claims
5. Tresiba Flextouch U-10048 claims
6. Novolog Flexpen43 claims

Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.

The practice group's MIPS final score for 2023 (Medicare payment program): 83 of 100

The Merit-based Incentive Payment System score is reported for the practice group, not for one clinician alone. Four categories are weighted into the final score; the average among 454,083 clinicians with a measured score was 83.5.

Source: CMS Quality Payment Program, MIPS performance year 2023, group reporting; category weights for 2023 (qpp.cms.gov).

Industry payments in 2024: $204.18

7 payments; by number, the most common kind was food and beverage; the largest payer was Rhythm Pharmaceuticals, Inc. The 5,661 providers of this specialty with any payment received $5,742.15 on average. Payments are reported by manufacturers, not by the provider, and are not a sign of wrongdoing.

Source: CMS Open Payments, program year 2024 (openpaymentsdata.cms.gov); average among providers of this specialty with at least one payment.

Bills Medicare through 3 group practices

1. Summa Physicians LLCAkron, OH
2. University OF Connecticut Health CenterFarmington, CT
3. University OF MiamiNorth Miami, FL

Source: CMS Doctors and Clinicians National Downloadable File (the group practices a clinician bills Medicare through) (data.cms.gov).